Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Becton Dickinson's Stock Is Worth Owning

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The next selection for the Inflation-Protected Income Growth Portfolio is medical device titan Becton, Dickinson and Company (NYSE: BDX  ) . In spite of the fact that the company expects slower earnings growth as a result of the new medical devices tax levied as part of Obamacare, it recently raised its dividend by 10%.  

That show of strength amid challenges is nothing new for the company, which has a history of raising dividends that stretches back for 41 consecutive fiscal years. When combined with a decent balance sheet and reasonable value, Becton Dickinson deserves a spot in this portfolio

Why it's worth owning in the iPIG Portfolio
To earn a spot in the portfolio, a company has to pass a series of tests related to its dividends, its balance sheet and valuation, and how it fits from a portfolio diversification perspective.


  • Payment: Becton Dickinson's dividend currently sits at $1.98 a share, a yield of about 2.3% based on Friday's closing price. 
  • Growth history: The company has raised its dividend at least once per fiscal year for the past 41 years. In Dec. 2012, it boosted the payment by 10%, from $0.45 to $0.495 per quarter.
  • Reason to believe the growth can continue: With a payout ratio of 32%, the company retains about two-thirds of its earnings to invest for future growth. That low payout ratio also gives the company flexibility to maintain its payment if that anticipated growth doesn't materialize as quickly as hoped.

Balance sheet and valuation:

  • Balance sheet: A debt-to-equity ratio just above 1.0 indicates that Becton Dickinson does use debt, but it hasn't overleveraged itself to the point where a near-term financial hiccup would derail it.

Valuation: The company easily passes a valuation test pioneered by none other than Benjamin Graham, the founder of value investing. That said, Graham's equation does take interest rates into account, and today's low rates make stock values seem cheaper than they would be in a more normal rate environment. Still, even dialing rates back up to more "normal" levels, Becton Dickinson would still look decently priced.

Diversification fit:
The previous picks for the portfolio included:

Like fellow iPIG portfolio pick Teva Pharmaceutical (NYSE: TEVA  ) , Becton Dickinson is in the business of helping people with medical conditions, which means it's not perfect from a diversification perspective. Still, it's different enough, given that Teva's strength is its generic-drug business, while Becton Dickinson shines making devices and other equipment that help with testing, treatment, and care. It may not be perfect diversification, but it's all part of the balancing act needed to manage across risks in investing.

What are the risks?
Of course, no investment is without risk. In Becton Dickinson's case, for instance, Obamacare's tax on its products showcases a regulatory risk that makes its products more expensive for consumers and/or investors.

Additionally, the bigger a company gets, the easier it is for the company to miss out on innovations that fundamentally change the market. Smaller competitor ICU Medical (NASDAQ: ICUI  ) , for instance, got its start and made its name filling niches in customization and safety that larger device players ignored. As a smaller, more nimble company, ICU Medical has more room for growth than its larger competition, but its lack of a dividend means it doesn't quite fit in this particular portfolio.

On the flip side, now that Abbot Laboratories (NYSE: ABT  ) has spun off its research-oriented pharmaceuticals business into AbbVie (NYSE: ABBV  ) , the old Abbot is now much more focused. With medical devices a key part of Abbot's focus, Becton Dickinson may find itself against some very hungry and dedicated competition that had, until recently, been distracted by the internal mechanics of the split-up.

What comes next?
When the Fool's disclosure policy allows, I plan to buy Becton Dickinson's stock for the Inflation-Protected Income Growth portfolio, as long as it remains below $88 a share. I expect to invest around $1,500 -- a 5% allocation in the portfolio -- with 25% of the portfolio still remaining in cash. Watch my article feed for details of the next pick, coming soon.

Also, to score the performance of this pick, I'm making an outperform CAPScall on the stock at Motley Fool CAPS, putting my All-Star ranking on the line along with the plan to invest cold, hard cash.

Wondering about that new position in your portfolio? For some Abbott Labs shareholders, the New Year brought with it a new company called AbbVie. Formerly Abbott's branded pharmaceuticals business, shares of the new stock were distributed to investors on Jan. 2. To help investors better understand the situation, the Fool has created a brand-new premium report on both stocks. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this report by clicking here now.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2220500, ~/Articles/ArticleHandler.aspx, 10/27/2016 11:10:30 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,206.80 7.47 0.04%
S&P 500 2,134.63 -4.80 -0.22%
NASD 5,238.48 -11.79 -0.22%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 10:53 AM
BDX $167.46 Down -0.09 -0.05%
Becton Dickinson CAPS Rating: ****
ABT $40.31 Up +0.35 +0.88%
Abbott Laboratorie… CAPS Rating: *****
ICUI $140.40 Down -3.35 -2.33%
ICU Medical CAPS Rating: ***
TEVA $43.43 Up +0.07 +0.16%
Teva Pharmaceutica… CAPS Rating: ****